Regulatory T cells (Tregs) are a subset of CD4+ T cells that have anti-inflammatory properties. In animal models, they have the ability to prevent rejection of allografts (tissue from another, genetically distinct animal) and to ameliorate the symtoms of autoimmune disease.

Our group manufactures Ex Vivo Expanded CD4⁺CD127^lo/-CD25⁺ Alloantigen- Reactive Regulatory T Cells (arTregs) and polyclonal CD4⁺CD127^lo/‐CD25⁺ regulatory T cells (polyclonal Tregs) for clinical trials in patients who have received solid organ tranplant or who have been diagnosed with an autoimmune disease. The goal is to test the safety and efficacy of these cells to prevent solid organ rejection or to improve symptoms of autoimmune disease.

These cellular therapy products are investigational new drugs limited by federal law for investigational use only. Polyclonal Tregs and arTregs are manufactured at the Human Islet and Cellular Transplantation Facility (HICTF) and GMP Facility, an FDA registered facility located at the University of California, San Francisco (UCSF).